ArcherDX Inc. signed a nonexclusive multiyear agreement with San Diego-based Illumina Inc. to co-market a portfolio of planned in vitro diagnostic test kits to detect cancer.
Boulder, Colo.-based ArcherDX is a private molecular technology company that develops solutions to advance the application of personalized genomic medicine.
Under the agreement, the companies will co-promote future ArcherDX's in vitro diagnostic, or IVD, tests that use Illumina's NextSeq 550Dx and MiSeq Dx systems. The tests will generate genomic information to determine optimal cancer treatment and provide clinicians and patients with information for cancer monitoring and recurrence surveillance.
Illumina's sequencing instruments, combined with ArcherDX's IVD kits and its software, will allow these platforms to guide clinical decision-making and targeted therapy, said ArcherDX CEO Jason Myers.
ArcherDX expects its Stratafide companion diagnostic to be the first IVD test to receive U.S. Food and Drug Administration approval under the partnership. The company plans to seek regulatory approval for its Personalized Cancer Monitoring product later.
Stratafide was granted the FDA's breakthrough device designation in early 2019.
ArcherDX and Illumina have previously worked together to develop, market and promote research products in markets outside the U.S.
Illumina signed a nonexclusive agreement Sept. 24, 2019, with Adaptive Biotechnologies Corp. to develop IVD test kits for cancer detection.